Last reviewed · How we verify
MVC-COV1901(3 Months)
MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.
MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection. Used for COVID-19 prevention in adults.
At a glance
| Generic name | MVC-COV1901(3 Months) |
|---|---|
| Sponsor | Taoyuan General Hospital |
| Drug class | Protein subunit vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant spike protein (S-2P) produced in mammalian cells, formulated with an aluminum adjuvant to enhance immunogenicity. It is administered as a 3-month regimen (typically 2 doses) to induce both humoral and cellular immune responses against the coronavirus spike protein, conferring protection against COVID-19 disease.
Approved indications
- Prevention of COVID-19 in adults
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVC-COV1901(3 Months) CI brief — competitive landscape report
- MVC-COV1901(3 Months) updates RSS · CI watch RSS
- Taoyuan General Hospital portfolio CI